GLP-1 drugs may reduce cravings across multiple addictions

Clinical observations, animal studies and an analysis of more than 600,000 VA patient records suggest people taking GLP-1 drugs had lower rates of substance-related deaths, overdoses and new substance use diagnoses, and several randomized trials are underway though the drugs are not approved for addiction.

GLP-1 drugs, developed for diabetes and later approved for obesity, have been linked in clinical reports and lab studies to reduced craving for food and, anecdotally, for alcohol, nicotine and other substances. A research team examined electronic health records from more than 600,000 people with Type 2 diabetes in the U.S. Department of Veterans Affairs to compare outcomes for patients who started GLP-1 drugs with those who did not. Animal experiments and several small clinical trials also reported lower substance use or reduced craving after GLP-1 treatment. The drugs are not approved for treating addiction, and researchers note unanswered questions about long-term effects and what happens if treatment stops. Key findings: - In the VA analysis, among people already struggling with addiction, GLP-1 drug use was associated with about 50% fewer deaths due to substance use, 39% fewer overdoses, 26% fewer drug-related hospitalizations and 25% fewer suicide attempts over three years. - Among people without a prior substance use disorder, GLP-1 drug use was associated with lower risks of new diagnoses: roughly 18% lower for alcohol use disorder, 25% lower for opioid use disorder and about 20% lower for cocaine and nicotine dependence over three years. - Animal studies showed reduced alcohol intake, less self-administration of cocaine and decreased interest in nicotine after GLP-1 treatment, and a primate study reported lower voluntary alcohol consumption without signs of nausea. - Several randomized clinical trials have reported reduced craving or drinking with GLP-1 agents in people with alcohol use disorder, and more than a dozen additional trials are underway or enrolling. Summary: If these findings are confirmed in ongoing and future randomized trials, GLP-1 drugs could change how some aspects of addiction are understood and treated, because they appear to act on shared brain reward pathways. Regulatory approval for addiction treatment has not been granted, and important questions remain about duration of effect, possible rebound after stopping treatment and long-term impacts on motivation. Further trials and longer-term data are the next stated steps in assessing safety and effectiveness.